Leukemia Explained

Leukemia
Synonyms:Leukaemia
Field:Hematology and oncology
Pronounce:[1]
Symptoms:Bleeding, bruising, fatigue, fever, increased risk of infections
Onset:All ages, most common in 60s and 70s. It is the most common malignant cancer in children, but the cure rates are also higher for them.
Causes:Inherited and environmental factors
Risks:Smoking, family history, ionizing radiation, some chemicals such as trichloroethylene, prior chemotherapy, Down syndrome.
Diagnosis:Blood tests, bone marrow biopsy
Treatment:Chemotherapy, radiation therapy, targeted therapy, bone marrow transplant, supportive care
Prognosis:Five-year survival rate 67% (U.S.)
Frequency:2.3 million (2015)
Deaths:353,500 (2015)

Leukemia (also spelled leukaemia; pronounced [1]) is a group of blood cancers that usually begin in the bone marrow and produce high numbers of abnormal blood cells.[2] These blood cells are not fully developed and are called blasts or leukemia cells.[3] Symptoms may include bleeding and bruising, bone pain, fatigue, fever, and an increased risk of infections. These symptoms occur due to a lack of normal blood cells. Diagnosis is typically made by blood tests or bone marrow biopsy.

The exact cause of leukemia is unknown. A combination of genetic factors and environmental (non-inherited) factors are believed to play a role.[4] Risk factors include smoking, ionizing radiation, petrochemicals (such as benzene), prior chemotherapy, and Down syndrome. People with a family history of leukemia are also at higher risk. There are four main types of leukemia—acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML)—and a number of less common types.[5] Leukemias and lymphomas both belong to a broader group of tumors that affect the blood, bone marrow, and lymphoid system, known as tumors of the hematopoietic and lymphoid tissues.[6] [7]

Treatment may involve some combination of chemotherapy, radiation therapy, targeted therapy, and bone marrow transplant, with supportive and palliative care provided as needed.[5] [8] Certain types of leukemia may be managed with watchful waiting.[5] The success of treatment depends on the type of leukemia and the age of the patient. Outcomes have improved in the developed world. Five-year survival rate was 67% in the United States in the period from 2014 to 2020.[9] In children under 15 in first-world countries, the five-year survival rate is greater than 60% or even 90%, depending on the type of leukemia. In children who are cancer-free five years after diagnosis of acute leukemia, the cancer is unlikely to return.[10]

In 2015, leukemia was present in 2.3 million people worldwide and caused 353,500 deaths.[11] [12] In 2012, it had newly developed in 352,000 people.[13] It is the most common type of cancer in children, with three-quarters of leukemia cases in children being the acute lymphoblastic type.[5] However, over 90% of all leukemias are diagnosed in adults, CLL and AML being most common.[5] [14] It occurs more commonly in the developed world.[13]

Classification

Four major kinds of leukemia! Cell type !! Acute !! Chronic
- Lymphocytic leukemia
(or "lymphoblastic") 		Acute lymphoblastic leukemia
(ALL) 		Chronic lymphocytic leukemia
(CLL) 		- Myelogenous leukemia
("myeloid" or "nonlymphocytic") 		Acute myelogenous leukemia
(AML or myeloblastic) 		Chronic myelogenous leukemia
(CML)

General classification

Clinically and pathologically, leukemia is subdivided into a variety of large groups. The first division is between its acute and chronic forms:[15]

Additionally, the diseases are subdivided according to which kind of blood cell is affected. This divides leukemias into lymphoblastic or lymphocytic leukemias and myeloid or myelogenous leukemias:

Combining these two classifications provides a total of four main categories. Within each of these main categories, there are typically several subcategories. Finally, some rarer types are usually considered to be outside of this classification scheme.[16]

Specific types

Pre-leukemia

Signs and symptoms

The most common symptoms in children are easy bruising, pale skin, fever, and an enlarged spleen or liver.[34]

Damage to the bone marrow, by way of displacing the normal bone marrow cells with higher numbers of immature white blood cells, results in a lack of blood platelets, which are important in the blood clotting process. This means people with leukemia may easily become bruised, bleed excessively, or develop pinprick bleeds (petechiae).[35]

White blood cells, which are involved in fighting pathogens, may be suppressed or dysfunctional. This could cause the person's immune system to be unable to fight off a simple infection or to start attacking other body cells. Because leukemia prevents the immune system from working normally, some people experience frequent infection, ranging from infected tonsils, sores in the mouth, or diarrhea to life-threatening pneumonia or opportunistic infections.[36]

Finally, the red blood cell deficiency leads to anemia, which may cause dyspnea and pallor.[37]

Some people experience other symptoms, such as fevers, chills, night sweats, weakness in the limbs, feeling fatigued and other common flu-like symptoms. Some people experience nausea or a feeling of fullness due to an enlarged liver and spleen; this can result in unintentional weight loss. Blasts affected by the disease may come together and become swollen in the liver or in the lymph nodes causing pain and leading to nausea.[38]

If the leukemic cells invade the central nervous system, then neurological symptoms (notably headaches) can occur. Uncommon neurological symptoms like migraines, seizures, or coma can occur as a result of brain stem pressure. All symptoms associated with leukemia can be attributed to other diseases. Consequently, leukemia is always diagnosed through medical tests.

The word leukemia, which means 'white blood', is derived from the characteristic high white blood cell count that presents in most affected people before treatment. The high number of white blood cells is apparent when a blood sample is viewed under a microscope, with the extra white blood cells frequently being immature or dysfunctional. The excessive number of cells can also interfere with the level of other cells, causing further harmful imbalance in the blood count.[39]

Some people diagnosed with leukemia do not have high white blood cell counts visible during a regular blood count. This less-common condition is called aleukemia. The bone marrow still contains cancerous white blood cells that disrupt the normal production of blood cells, but they remain in the marrow instead of entering the bloodstream, where they would be visible in a blood test. For a person with aleukemia, the white blood cell counts in the bloodstream can be normal or low. Aleukemia can occur in any of the four major types of leukemia, and is particularly common in hairy cell leukemia.

Causes

Studies in 2009 and 2010 have shown a positive correlation between exposure to formaldehyde and the development of leukemia, particularly myeloid leukemia.[40] [41] The different leukemias likely have different causes.[42]

Leukemia, like other cancers, results from mutations in the DNA. Certain mutations can trigger leukemia by activating oncogenes or deactivating tumor suppressor genes, and thereby disrupting the regulation of cell death, differentiation or division. These mutations may occur spontaneously or as a result of exposure to radiation or carcinogenic substances.[43]

Among adults, the known causes are natural and artificial ionizing radiation and petrochemicals, notably benzene and alkylating chemotherapy agents for previous malignancies.[44] [45] [46] Use of tobacco is associated with a small increase in the risk of developing acute myeloid leukemia in adults. Cohort and case-control studies have linked exposure to some petrochemicals and hair dyes to the development of some forms of leukemia. Diet has very limited or no effect, although eating more vegetables may confer a small protective benefit.[47]

Viruses have also been linked to some forms of leukemia. For example, human T-lymphotropic virus (HTLV-1) causes adult T-cell leukemia.[48]

A few cases of maternal-fetal transmission (a baby acquires leukemia because its mother had leukemia during the pregnancy) have been reported. Children born to mothers who use fertility drugs to induce ovulation are more than twice as likely to develop leukemia during their childhoods than other children.[49]

In a recent systematic review and meta-analysis of any type of leukemia in neonates using phototherapy, typically to treat neonatal jaundice, a statistically significant association was detected between using phototherapy and myeloid leukemia. However, it is still questionable whether phototherapy is genuinely the cause of cancer or simply a result of the same underlying factors that gave rise to cancer. [50]

Radiation

Large doses of Sr-90 (called a bone seeking radioisotope) from nuclear reactor accidents, increases the risk of bone cancer and leukemia in animals and is presumed to do so in people.[51]

Genetic conditions

Some people have a genetic predisposition towards developing leukemia. This predisposition is demonstrated by family histories and twin studies. The affected people may have a single gene or multiple genes in common. In some cases, families tend to develop the same kinds of leukemia as other members; in other families, affected people may develop different forms of leukemia or related blood cancers.

In addition to these genetic issues, people with chromosomal abnormalities or certain other genetic conditions have a greater risk of leukemia. For example, people with Down syndrome have a significantly increased risk of developing forms of acute leukemia (especially acute myeloid leukemia), and Fanconi anemia is a risk factor for developing acute myeloid leukemia. Mutation in SPRED1 gene has been associated with a predisposition to childhood leukemia.[52]

Inherited bone marrow failure syndromes represent a kind of premature aging of the bone marrow. In patients with these syndromes and in elderly patients, mutations associated with clonal hematopoiesis may arise as an adaptive response to a progressively deteriorating hematopoietic niche, i.e., a depleting pool of Hematopoietic stem cells. The mutated stem cells then acquire a self-renewal advantage.[53]

Chronic myelogenous leukemia is associated with a genetic abnormality called the Philadelphia translocation; 95% of people with CML carry the Philadelphia mutation, although this is not exclusive to CML and can be observed in people with other types of leukemia.[54] [55] [56] [57]

Non-ionizing radiation

Whether or not non-ionizing radiation causes leukemia has been studied for several decades. The International Agency for Research on Cancer expert working group undertook a detailed review of all data on static and extremely low frequency electromagnetic energy, which occurs naturally and in association with the generation, transmission, and use of electrical power.[58] They concluded that there is limited evidence that high levels of ELF magnetic (but not electric) fields might cause some cases of childhood leukemia. No evidence for a relationship to leukemia or another form of malignancy in adults has been demonstrated. Since exposure to such levels of ELFs is relatively uncommon, the World Health Organization concludes that ELF exposure, if later proven to be causative, would account for just 100 to 2400 cases worldwide each year, representing 0.2 to 4.9% of the total incidence of childhood leukemia for that year (about 0.03 to 0.9% of all leukemias).[59]

Diagnosis

Diagnosis is usually based on repeated complete blood counts and a bone marrow examination following observations of the symptoms. Sometimes, blood tests may not show that a person has leukemia, especially in the early stages of the disease or during remission. A lymph node biopsy can be performed to diagnose certain types of leukemia in certain situations.[60]

Following diagnosis, blood chemistry tests can be used to determine the degree of liver and kidney damage or the effects of chemotherapy on the person. When concerns arise about other damages due to leukemia, doctors may use an X-ray, MRI, or ultrasound. These can potentially show leukemia's effects on such body parts as bones (X-ray), the brain (MRI), or the kidneys, spleen, and liver (ultrasound). CT scans can be used to check lymph nodes in the chest, though this is uncommon.[61]

Despite the use of these methods to diagnose whether or not a person has leukemia, many people have not been diagnosed because many of the symptoms are vague, non-specific, and can refer to other diseases. For this reason, the American Cancer Society estimates that at least one-fifth of the people with leukemia have not yet been diagnosed.[62]

Treatment

Most forms of leukemia are treated with pharmaceutical medication, typically combined into a multi-drug chemotherapy regimen. Some are also treated with radiation therapy. In some cases, a bone marrow transplant is effective.

Acute lymphoblastic

Management of ALL is directed towards control of bone marrow and systemic (whole-body) disease. Additionally, treatment must prevent leukemic cells from spreading to other sites, particularly the central nervous system (CNS); periodic lumbar punctures are used for diagnostic purposes and to administer intrathecal prophylactic methotrexate.[63] In general, ALL treatment is divided into several phases:

Chronic lymphocytic

Decision to treat

Hematologists base CLL treatment on both the stage and symptoms of the individual person. A large group of people with CLL have low-grade disease, which does not benefit from treatment. Individuals with CLL-related complications or more advanced disease often benefit from treatment. In general, the indications for treatment are:

Treatment approach

Most CLL cases are incurable by present treatments, so treatment is directed towards suppressing the disease for many years, rather than curing it. The primary chemotherapeutic plan is combination chemotherapy with chlorambucil or cyclophosphamide, plus a corticosteroid such as prednisone or prednisolone. The use of a corticosteroid has the additional benefit of suppressing some related autoimmune diseases, such as immunohemolytic anemia or immune-mediated thrombocytopenia. In resistant cases, single-agent treatments with nucleoside drugs such as fludarabine,[66] pentostatin, or cladribine may be successful. Younger and healthier people may choose allogeneic or autologous bone marrow transplantation in the hope of a permanent cure.[67]

Acute myelogenous

Many different anti-cancer drugs are effective for the treatment of AML. Treatments vary somewhat according to the age of the person and according to the specific subtype of AML. Overall, the strategy is to control bone marrow and systemic (whole-body) disease, while offering specific treatment for the central nervous system (CNS), if involved.[68]

In general, most oncologists rely on combinations of drugs for the initial, induction phase of chemotherapy. Such combination chemotherapy usually offers the benefits of early remission and a lower risk of disease resistance. Consolidation and maintenance treatments are intended to prevent disease recurrence. Consolidation treatment often entails a repetition of induction chemotherapy or the intensification of chemotherapy with additional drugs. By contrast, maintenance treatment involves drug doses that are lower than those administered during the induction phase.[69]

Chronic myelogenous

There are many possible treatments for CML, but the standard of care for newly diagnosed people is imatinib (Gleevec) therapy.[70] Compared to most anti-cancer drugs, it has relatively few side effects and can be taken orally at home. With this drug, more than 90% of people will be able to keep the disease in check for at least five years,[70] so that CML becomes a chronic, manageable condition.

In a more advanced, uncontrolled state, when the person cannot tolerate imatinib, or if the person wishes to attempt a permanent cure, then an allogeneic bone marrow transplantation may be performed. This procedure involves high-dose chemotherapy and radiation followed by infusion of bone marrow from a compatible donor. Approximately 30% of people die from this procedure.[70]

Hairy cell

Decision to treat
People with hairy cell leukemia who are symptom-free typically do not receive immediate treatment. Treatment is generally considered necessary when the person shows signs and symptoms such as low blood cell counts (e.g., infection-fighting neutrophil count below 1.0 K/μL), frequent infections, unexplained bruises, anemia, or fatigue that is significant enough to disrupt the person's everyday life.[71]

Typical treatment approach
People who need treatment usually receive either one week of cladribine, given daily by intravenous infusion or a simple injection under the skin, or six months of pentostatin, given every four weeks by intravenous infusion. In most cases, one round of treatment will produce a prolonged remission.[72]

Other treatments include rituximab infusion or self-injection with Interferon-alpha. In limited cases, the person may benefit from splenectomy (removal of the spleen). These treatments are not typically given as the first treatment because their success rates are lower than cladribine or pentostatin.[73]

T-cell prolymphocytic

Most people with T-cell prolymphocytic leukemia, a rare and aggressive leukemia with a median survival of less than one year, require immediate treatment.[74]

T-cell prolymphocytic leukemia is difficult to treat, and it does not respond to most available chemotherapeutic drugs. Many different treatments have been attempted, with limited success in certain people: purine analogues (pentostatin, fludarabine, cladribine), chlorambucil, and various forms of combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone CHOP, cyclophosphamide, vincristine, prednisone [COP], vincristine, doxorubicin, prednisone, etoposide, cyclophosphamide, bleomycin VAPEC-B). Alemtuzumab (Campath), a monoclonal antibody that attacks white blood cells, has been used in treatment with greater success than previous options.

Some people who successfully respond to treatment also undergo stem cell transplantation to consolidate the response.

Juvenile myelomonocytic

Treatment for juvenile myelomonocytic leukemia can include splenectomy, chemotherapy, and bone marrow transplantation.[75]

Prognosis

The success of treatment depends on the type of leukemia and the age of the person. Outcomes have improved in the developed world.[13] The average five-year survival rate is 65% in the United States.[9] In children under 15, the five-year survival rate is greater (60 to 85%), depending on the type of leukemia.[10] In children with acute leukemia who are cancer-free after five years, the cancer is unlikely to return.[10]

Outcomes depend on whether it is acute or chronic, the specific abnormal white blood cell type, the presence and severity of anemia or thrombocytopenia, the degree of tissue abnormality, the presence of metastasis and lymph node and bone marrow infiltration, the availability of therapies and the skills of the health care team. Treatment outcomes may be better when people are treated at larger centers with greater experience.[76]

Epidemiology

In 2010, globally, approximately 281,500 people died of leukemia.[77] In 2000, approximately 256,000 children and adults around the world developed a form of leukemia, and 209,000 died from it.[78] This represents about 3% of the almost seven million deaths due to cancer that year, and about 0.35% of all deaths from any cause. Of the sixteen separate sites the body compared, leukemia was the 12th most common class of neoplastic disease and the 11th most common cause of cancer-related death. Leukemia occurs more commonly in the developed world.[79]

United States

About 245,000 people in the United States are affected with some form of leukemia, including those that have achieved remission or cure. Rates from 1975 to 2011 have increased by 0.7% per year among children.[80] Approximately 44,270 new cases of leukemia were diagnosed in the year 2008 in the US.[81] This represents 2.9% of all cancers (excluding simple basal cell and squamous cell skin cancers) in the United States, and 30.4% of all blood cancers.[82]

Among children with some form of cancer, about a third have a type of leukemia, most commonly acute lymphoblastic leukemia. A type of leukemia is the second most common form of cancer in infants (under the age of 12 months) and the most common form of cancer in older children.[83] Boys are somewhat more likely to develop leukemia than girls, and white American children are almost twice as likely to develop leukemia than black American children. Only about 3% cancer diagnoses among adults are for leukemias, but because cancer is much more common among adults, more than 90% of all leukemias are diagnosed in adults.

Race is a risk factor in the United States. Hispanics, especially those under the age of 20, are at the highest risk for leukemia, while whites, Native Americans, Asian Americans, and Alaska Natives are at higher risk than African Americans.[84]

More men than women are diagnosed with leukemia and die from the disease. Around 30 percent more men than women have leukemia.[85]

Australia

In Australia, leukemia is the eleventh most common cancer.[86] In 2014–2018, Australians diagnosed with leukemia had a 64% chance (65% for males and 64% for females) of surviving for five years compared to the rest of the Australian population–there was a 21% increase in survival rates between 1989–1993.

UK

Overall, leukemia is the eleventh most common cancer in the UK (around 8,600 people were diagnosed with the disease in 2011), and it is the ninth most common cause of cancer death (around 4,800 people died in 2012).[87]

History

Leukemia was first described by anatomist and surgeon Alfred-Armand-Louis-Marie Velpeau in 1827. A more complete description was given by pathologist Rudolf Virchow in 1845. Around ten years after Virchow's findings, pathologist Franz Ernst Christian Neumann found that the bone marrow of a deceased person with leukemia was colored "dirty green-yellow" as opposed to the normal red. This finding allowed Neumann to conclude that a bone marrow problem was responsible for the abnormal blood of people with leukemia.[88]

By 1900, leukemia was viewed as a family of diseases as opposed to a single disease. By 1947, Boston pathologist Sidney Farber believed from past experiments that aminopterin, a folic acid mimic, could potentially cure leukemia in children. The majority of the children with ALL who were tested showed signs of improvement in their bone marrow, but none of them were actually cured. Nevertheless, this result did lead to further experiments.[89]

In 1962, researchers Emil J. Freireich, Jr. and Emil Frei III used combination chemotherapy to attempt to cure leukemia. The tests were successful with some people surviving long after the tests.[90]

Etymology

Observing an abnormally large number of white blood cells in a blood sample from a person, Virchow called the condition Leukämie in German, which he formed from the two Greek words leukos (λευκός), meaning 'white', and haima (αἷμα), meaning 'blood'.[91] It was formerly also called leucemia.[92]

Society and culture

According to Susan Sontag, leukemia was often romanticized in 20th-century fiction, portrayed as a joy-ending, clean disease whose fair, innocent and gentle victims die young or at the wrong time. As such, it was the cultural successor to tuberculosis, which held this cultural position until it was discovered to be an infectious disease.[93] The 1970 romance novel Love Story is an example of this romanticization of leukemia.[94]

In the United States, around $5.4 billion is spent on treatment a year.[95]

Research directions

Significant research into the causes, prevalence, diagnosis, treatment, and prognosis of leukemia is being performed. Hundreds of clinical trials are being planned or conducted at any given time.[96] Studies may focus on effective means of treatment, better ways of treating the disease, improving the quality of life for people, or appropriate care in remission or after cures.[97]

In general, there are two types of leukemia research: clinical or translational research and basic research. Clinical/translational research focuses on studying the disease in a defined and generally immediately applicable way, such as testing a new drug in people. By contrast, basic science research studies the disease process at a distance, such as seeing whether a suspected carcinogen can cause leukemic changes in isolated cells in the laboratory or how the DNA changes inside leukemia cells as the disease progresses. The results from basic research studies are generally less immediately useful to people with the disease.[98]

Treatment through gene therapy is currently being pursued. One such approach used genetically modified T cells, known as chimeric antigen receptor T cells (CAR-T cells), to attack cancer cells. In 2011, a year after treatment, two of the three people with advanced chronic lymphocytic leukemia were reported to be cancer-free[99] and in 2013, three of five subjects who had acute lymphocytic leukemia were reported to be in remission for five months to two years.[100] Subsequent studies with a variety of CAR-T types continue to be promising.[101] As of 2018, two CAR-T therapies have been approved by the Food and Drug Administration. CAR-T treatment has significant side effects,[102] and loss of the antigen targeted by the CAR-T cells is a common mechanism for relapse. The stem cells that cause different types of leukemia are also being researched.[103]

Pregnancy

Leukemia is rarely associated with pregnancy, affecting only about 1 in 10,000 pregnant women. How it is handled depends primarily on the type of leukemia. Nearly all leukemias appearing in pregnant women are acute leukemias.[104] Acute leukemias normally require prompt, aggressive treatment, despite significant risks of pregnancy loss and birth defects, especially if chemotherapy is given during the developmentally sensitive first trimester. Chronic myelogenous leukemia can be treated with relative safety at any time during pregnancy with Interferon-alpha hormones. Treatment for chronic lymphocytic leukemias, which are rare in pregnant women, can often be postponed until after the end of the pregnancy.[105]

See also

External links

Notes and References

  1. Leukemia . 30 May 2023 . Merriam-Webster .
  2. Web site: Leukemia. NCI. 13 June 2014. live. https://web.archive.org/web/20140527085758/http://www.cancer.gov/cancertopics/types/leukemia. 27 May 2014. 1 January 1980. Cancer that starts in blood-forming tissue, such as the bone marrow, and causes large numbers of abnormal blood cells.
  3. Web site: What You lNeed To Know About Leukemia. National Cancer Institute. 18 June 2014. 23 December 2013. live. https://web.archive.org/web/20140706152110/http://www.cancer.gov/cancertopics/wyntk/leukemia/page2/AllPages. 6 July 2014.
  4. Hutter JJ . Childhood leukemia . Pediatrics in Review . 31 . 6 . 234–241 . June 2010 . 20516235 . 10.1542/pir.31-6-234 . 207170780 .
  5. Web site: A Snapshot of Leukemia. NCI. 18 June 2014. live. https://web.archive.org/web/20140704183430/http://www.cancer.gov/researchandfunding/snapshots/leukemia. 4 July 2014.
  6. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes . Blood . 114 . 5 . 937–951 . July 2009 . 19357394 . 10.1182/blood-2009-03-209262 . 3101472 . free .
  7. Book: Baba AI, Câtoi C . Comparative oncology. 2007. The Publishing House of the Romanian Academy. Bucharest. 978-973-27-1457-7. Chapter 17. live. https://web.archive.org/web/20170910174530/https://www.ncbi.nlm.nih.gov/books/NBK9562/. 10 September 2017.
  8. Cordo' V, van der Zwet JC, Canté-Barrett K, Pieters R, Meijerink JP . T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies . Blood Cancer Discovery . 2 . 1 . 19–31 . January 2021 . 34661151 . 8447273 . 10.1158/2643-3230.BCD-20-0093 . free .
  9. Web site: SEER Stat Fact Sheets: Leukemia. 2024. National Cancer Institute. dmy-all. Updated as required.
  10. Web site: American Cancer Society. Survival rates for childhood leukemia. 2 March 2014. live. https://web.archive.org/web/20140714204805/http://www.cancer.org/cancer/leukemiainchildren/overviewguide/childhood-leukemia-overview-survival-rates. 14 July 2014.
  11. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 . Lancet . 388 . 10053 . 1545–1602 . October 2016 . 27733282 . 5055577 . 10.1016/S0140-6736(16)31678-6 . Vos . Theo . Allen . Christine . Arora . Megha . Barber . Ryan M. . Bhutta . Zulfiqar A. . Brown . Alexandria . Carter . Austin . Casey . Daniel C. . Charlson . Fiona J. . Chen . Alan Z. . Coggeshall . Megan . Cornaby . Leslie . Dandona . Lalit . Dicker . Daniel J. . Dilegge . Tina . Erskine . Holly E. . Ferrari . Alize J. . Fitzmaurice . Christina . Fleming . Tom . Forouzanfar . Mohammad H. . Fullman . Nancy . Gething . Peter W. . Goldberg . Ellen M. . Graetz . Nicholas . Haagsma . Juanita A. . Hay . Simon I. . Johnson . Catherine O. . Kassebaum . Nicholas J. . Kawashima . Toana . Kemmer . Laura .
  12. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 . Lancet . 388 . 10053 . 1459–1544 . October 2016 . 27733281 . 5388903 . 10.1016/s0140-6736(16)31012-1 . Wang . Haidong . Naghavi . Mohsen . Allen . Christine . Barber . Ryan M. . Bhutta . Zulfiqar A. . Carter . Austin . Casey . Daniel C. . Charlson . Fiona J. . Chen . Alan Zian . Coates . Matthew M. . Coggeshall . Megan . Dandona . Lalit . Dicker . Daniel J. . Erskine . Holly E. . Ferrari . Alize J. . Fitzmaurice . Christina . Foreman . Kyle . Forouzanfar . Mohammad H. . Fraser . Maya S. . Fullman . Nancy . Gething . Peter W. . Goldberg . Ellen M. . Graetz . Nicholas . Haagsma . Juanita A. . Hay . Simon I. . Huynh . Chantal . Johnson . Catherine O. . Kassebaum . Nicholas J. . Kinfu . Yohannes . Kulikoff . Xie Rachel .
  13. Book: World Cancer Report 2014.. 2014. World Health Organization. 978-92-832-0429-9. Chapter 5.13.
  14. Web site: Chronic Lymphocytic Leukemia (CLL) – Hematology and Oncology. MSD Manual Professional Edition. en-PT. 2020-02-01.
  15. Web site: Questions and Answers About Leukemia . live . https://web.archive.org/web/20210730115224/https://www.cdc.gov/nceh/radiation/phase2/mleukemi.pdf . July 30, 2021 . August 8, 2021 . Centers for Disease Control and Prevention.
  16. Web site: Leukemia – Symptoms and causes. 2021-08-08. Mayo Clinic. en.
  17. Web site: Key Statistics for Acute Lymphocytic Leukemia (ALL). 8 January 2019 . American Cancer Society . 9 December 2019.
  18. Web site: Finding Cancer Statistics » Cancer Stat Fact Sheets »Chronic Lymphocytic Leukemia . https://web.archive.org/web/20080416053309/http://seer.cancer.gov/statfacts/html/clyl.html. 16 April 2008 . National Cancer Institute .
  19. Web site: Survival: Acute Myeloid Leukaemia . 10 July 2019 . Cancer Research UK . 2 December 2019.
  20. Web site: Novartis Oncology. live. https://web.archive.org/web/20131105145436/http://www.novartisoncology.com/. 5 November 2013.
  21. Web site: Moyer P . 12 June 2006 . Patients with Chronic Myelogenous Leukemia Continue to Do Well on Imatinib at 5-Year Follow-Up . https://web.archive.org/web/20130515063623/http://www.medscape.com/viewarticle/536049 . 15 May 2013 . Medscape Medical News .
  22. Web site: Updated Results of Tyrosine Kinase Inhibitors in CML . https://web.archive.org/web/20071229125528/http://professional.cancerconsultants.com/conference_asco_2006.aspx?id=37519 . 29 December 2007 . ASCO 2006 Conference Summaries .
  23. Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D . Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years . Cancer . 104 . 11 . 2442–2448 . December 2005 . 16245328 . 10.1002/cncr.21447 . 43282431 . free .
  24. Matutes E . T-cell Prolymphocytic Leukemia . Cancer Control . 5 . 1 . 19–24 . January 1998 . 10761013 . 10.1177/107327489800500102 . live . free . https://web.archive.org/web/20090211044933/http://www.moffitt.org/moffittapps/ccj/v5n1/article2.html . 11 February 2009 .
  25. Valbuena JR, Herling M, Admirand JH, Padula A, Jones D, Medeiros LJ . T-cell prolymphocytic leukemia involving extramedullary sites . American Journal of Clinical Pathology . 123 . 3 . 456–464 . March 2005 . 15716243 . 10.1309/93P4-2RNG-5XBG-3KBE . live . free . https://web.archive.org/web/20130515093513/http://www.medscape.com/viewarticle/501092 . 15 May 2013 .
  26. Book: Jaffe ES, Harris NL, Stein H, Vardiman JW . World Health Organization, International Agency for Research on Cancer . Pathology and genetics of tumours of haematopoietic and lymphoid tissues . IARC Press . Lyon . 2001 . World Health Organization Classification of Tumors . 3 . 978-92-832-2411-2 .
  27. Reiter A, Gotlib J . Myeloid neoplasms with eosinophilia . Blood . 129 . 6 . 704–714 . February 2017 . 28028030 . 10.1182/blood-2016-10-695973 . free .
  28. Gotlib J . World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management . American Journal of Hematology . 90 . 11 . 1077–1089 . November 2015 . 26486351 . 10.1002/ajh.24196 . 42668440 . free .
  29. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia . Blood . 127 . 20 . 2391–2405 . May 2016 . 27069254 . 10.1182/blood-2016-03-643544 . 18338178 . free .
  30. Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I . Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update . Current Hematologic Malignancy Reports . 11 . 5 . 333–341 . October 2016 . 27510823 . 5031718 . 10.1007/s11899-016-0338-x .
  31. Crispino JD, Horwitz MS . GATA factor mutations in hematologic disease . Blood . 129 . 15 . 2103–2110 . April 2017 . 28179280 . 5391620 . 10.1182/blood-2016-09-687889 .
  32. Seewald L, Taub JW, Maloney KW, McCabe ER . Acute leukemias in children with Down syndrome . Molecular Genetics and Metabolism . 107 . 1–2 . 25–30 . September 2012 . 22867885 . 10.1016/j.ymgme.2012.07.011 .
  33. Weeks LD, Ebert BL. Causes and consequences of clonal hematopoiesis. Blood. 2023 Dec 28;142(26):2235–2246. doi: 10.1182/blood.2023022222. PMID: 37931207; PMCID: PMC10862247.
  34. Clarke RT, Van den Bruel A, Bankhead C, Mitchell CD, Phillips B, Thompson MJ . Clinical presentation of childhood leukaemia: a systematic review and meta-analysis . Archives of Disease in Childhood . 101 . 10 . 894–901 . October 2016 . 27647842 . 10.1136/archdischild-2016-311251 . free .
  35. Jyothi KT, Subrahmanyam PS, Sravanthi AC . July 2017 . Application of Differential Equations in Medical Science . Research Journal of Science and Technology . 9 . 3 . 425–426 . 10.5958/2349-2988.2017.00074.2 .
  36. Web site: 2018-10-05. Types of Leukemia: Common, Rare and More Varieties. 2021-10-08. Cancer Treatment Centers of America. en.
  37. Web site: Iron deficiency anemia – Symptoms and causes . 2022-03-05 . Mayo Clinic . en.
  38. Web site: Leukemia. Columbia Electronic Encyclopedia, 6th Edition. 4 November 2011.
  39. Web site: Leukemia: Symptoms, Signs, Causes, Types & Treatment . 2022-10-13 . Cleveland Clinic.
  40. Zhang. Luoping. Steinmaus. Craig. Eastmond. Eastmond. Xin. Xin. Smith. Smith. Formaldehyde exposure and leukemia: A new meta-analysis and potential mechanisms. March–June 2009. 681. 150–168. 18674636. 10.1016/j.mrrev.2008.07.002. 2013-05-22. Mutation Research/Reviews in Mutation Research. 2–3. https://web.archive.org/web/20140327073359/http://ehs.sph.berkeley.edu/krsmith/CRA/cancer/ZhangL_2008.pdf. 2014-03-27. dead.
  41. 10.1002/em.20534. 19790261. Formaldehyde and Leukemia: Epidemiology, Potential Mechanisms, and Implications for Risk Assessment. 2010. 51. 3. 181–191. Environmental and Molecular Mutagenesis. 2839060. Zhang. Luoping. Freeman. Laura E. Beane. Nakamura. Jun. Hecht. Stephen S.. Vandenberg. John J.. Smith. Martyn T.. Sonawane. Babasaheb R.. 2010EnvMM..51..181Z.
  42. Book: Novak EM, Rego EM . Physiopathogenesis of Hematological Cancer . Bentham Science Publishers . 2012 . 978-1-60805-259-2 .
  43. Radivoyevitch T, Sachs RK, Gale RP, Molenaar RJ, Brenner DJ, Hill BT, Kalaycio ME, Carraway HE, Mukherjee S, Sekeres MA, Maciejewski JP . Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation . Leukemia . 30 . 2 . 285–294 . February 2016 . 26460209 . 10.1038/leu.2015.258 . 22100511 .
  44. Book: Wiernik PH . Adult leukemias. B. C. Decker. New York. 2001. 3–15. 978-1-55009-111-3.
  45. Book: Robinette MS, Cotter S, Van de Water D . Quick Look Series in Veterinary Medicine: Hematology. Teton NewMedia. 2001. 105. 978-1-893441-36-1.
  46. Book: Stass SA, Schumacher HR, Rock WR . Handbook of hematologic pathology. limited . Marcel Dekker. New York, N.Y. 2000. 193–194. 978-0-8247-0170-3.
  47. Ross JA, Kasum CM, Davies SM, Jacobs DR, Folsom AR, Potter JD . Diet and risk of leukemia in the Iowa Women's Health Study . Cancer Epidemiology, Biomarkers & Prevention . 11 . 8 . 777–781 . August 2002 . 12163333 . live . https://web.archive.org/web/20170910174529/http://cebp.aacrjournals.org/content/11/8/777.long . 10 September 2017 .
  48. Book: Leonard B . Leukemia: A Research Report. 1998. DIANE Publishing. 978-0-7881-7189-5. 7.
  49. Rudant J, Amigou A, Orsi L, Althaus T, Leverger G, Baruchel A, Bertrand Y, Nelken B, Plat G, Michel G, Sirvent N, Chastagner P, Ducassou S, Rialland X, Hémon D, Clavel J . Fertility treatments, congenital malformations, fetal loss, and childhood acute leukemia: the ESCALE study (SFCE) . Pediatric Blood & Cancer . 60 . 2 . 301–308 . February 2013 . 22610722 . 10.1002/pbc.24192 . 26010916 .
  50. Abdellatif, Mohammed, et al. "Association between neonatal phototherapy and future cancer: an updated systematic review and meta-analysis." European Journal of Pediatrics (2022): 1–13.
  51. Web site: Backgrounder on Radiation Protection and the "Tooth Fairy" Issue . https://web.archive.org/web/20170720060330/https://www.nrc.gov/reading-rm/doc-collections/fact-sheets/tooth-fairy.html . 20 July 2017 . U.S. Nuclear Regulatory Commission . December 2004 .
  52. Pasmant E, Ballerini P, Lapillonne H, Perot C, Vidaud D, Leverger G, Landman-Parker J . SPRED1 disorder and predisposition to leukemia in children . Blood . 114 . 5 . 1131 . July 2009 . 19643996 . 10.1182/blood-2009-04-218503 . free .
  53. Hall T, Gurbuxani S, Crispino JD. Malignant progression of preleukemic disorders. Blood. 2024 May 30;143(22):2245–2255. doi: 10.1182/blood.2023020817. PMID: 38498034; PMCID: PMC11181356.
  54. Salesse S, Verfaillie CM . BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia . Oncogene . 21 . 56 . 8547–8559 . December 2002 . 12476301 . 10.1038/sj.onc.1206082 . free .
  55. Web site: NCI Dictionary of Cancer Terms. National Cancer Institute. en. 15 February 2017. live. https://web.archive.org/web/20170216141643/https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=44179. 16 February 2017. 2 February 2011.
  56. Web site: Do We Know What Causes Chronic Myeloid Leukemia?. www.cancer.org. 15 February 2017. live. https://web.archive.org/web/20170216144606/https://www.cancer.org/cancer/chronic-myeloid-leukemia/causes-risks-prevention/what-causes.html. 16 February 2017.
  57. Web site: What is chronic myeloid leukaemia? (CML) – Understanding – Macmillan Cancer Support. www.macmillan.org.uk. en. 15 February 2017. live. https://web.archive.org/web/20170216133037/http://www.macmillan.org.uk/information-and-support/leukaemia/leukaemia-chronic-myeloid/understanding-cancer/what-is-leukaemia.html. 16 February 2017.
  58. Book: Non-Ionizing Radiation, Part 1: Static and Extremely Low-Frequency (ELF) Electric and Magnetic Fields (IARC Monographs on the Evaluation of the Carcinogenic Risks). World Health Organisation. Geneva. 2002. 332–333, 338. 978-92-832-1280-5. live. https://web.archive.org/web/20081206231737/http://monographs.iarc.fr/ENG/Monographs/vol80/index.php. 6 December 2008.
  59. Web site: WHO | Electromagnetic fields and public health. 18 February 2009. dead. https://web.archive.org/web/20090216160809/http://www.who.int/mediacentre/factsheets/fs322/en/index.html. 16 February 2009.
  60. Web site: Diagnosing Chronic Lymphocytic Leukemia in Adults . live . https://archive.today/20210326200439/https://nyulangone.org/conditions/chronic-lymphocytic-leukemia-in-adults/diagnosis . 2021-03-26 . 2021-03-26 . NYU Langone Health.
  61. Web site: Chronic Lymphocytic Leukemia (CLL): Tests After Diagnosis . live . https://archive.today/20210326200920/https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=34&contentid=BCLL04 . 2021-03-26 . 2021-03-26 . University of Rochester Medical Center .
  62. Web site: How is Leukemia Diagnosed? . American Cancer Society . 2010 . Detailed Guide: Leukemia – Adult Chronic . American Cancer Society . 4 May 2010 . dead . https://web.archive.org/web/20100405215530/http://www.cancer.org/docroot/cri/content/cri_2_4_3x_how_is_leukemia_diagnosed_62.asp . 5 April 2010 .
  63. Gaietto A, Panetta JC, Pauley JL, Relling MV, Ribeiro R, Ehrhardt MJ, Pui CH, Inaba H, Swanson HD. Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children's Research Hospital. Cancer Chemother Pharmacol. 2024 Jun;93(6):617–625. doi: 10.1007/s00280-024-04653-9. Epub 2024 Feb 28. PMID: 38416167.
  64. Book: Hoffbrand AV, Moss PA, Pettit JE . Essential haematology. 2006. Blackwell Pub. . Malden, Mass. . 978-1-4051-3649-5 . 5th.
  65. Web site: Chronic Lymphocytic Leukemia (PDQ) Treatment: Stage Information . National Cancer Institute . 4 September 2007 . live . https://web.archive.org/web/20071017143320/http://www.cancer.gov/cancertopics/pdq/treatment/CLL/HealthProfessional/page2 . 17 October 2007 . 1 January 1980 .
  66. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jäger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Döhner H, Brittinger G, Emmerich B, Hallek M . Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia . Blood . 107 . 3 . 885–891 . February 2006 . 16219797 . 10.1182/blood-2005-06-2395 . free .
  67. Gribben JG . Stem cell transplantation in chronic lymphocytic leukemia . Biology of Blood and Marrow Transplantation . 15 . 1 Suppl . 53–58 . January 2009 . 19147079 . 2668540 . 10.1016/j.bbmt.2008.10.022 .
  68. Book: Baig MQ . Practical Radiotherapy & Chemotherapy Planning . 2017-03-22 . JP Medical Ltd . 978-93-86150-01-1 . en.
  69. Web site: Typical treatment of acute myeloid leukemia (except promyelocytic M3). American Cancer Society. 22 March 2012. Detailed Guide: Leukemia – Acute Myeloid (AML). American Cancer Society. 31 October 2012. live. https://web.archive.org/web/20121112202809/http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-treating-typical-treatment-of-aml. 12 November 2012.
  70. Fausel C . Targeted chronic myeloid leukemia therapy: seeking a cure . Journal of Managed Care Pharmacy . 13 . 8 Suppl A . 8–12 . October 2007 . 17970609 . 10.18553/jmcp.2007.13.s8-a.8 . 10437886 . dead . 18 May 2008 . https://web.archive.org/web/20080528041331/http://www.amcp.org/data/jmcp/pages%208-12.pdf . 28 May 2008 .
  71. Web site: Hairy Cell Leukemia. The Lecturio Medical Concept Library . 24 July 2021.
  72. Robak T, Jamroziak K, Gora-Tybor J, Blonski JZ, Kasznicki M, Dwilewicz-Trojaczek J, Wiater E, Zdunczyk A, Dybowicz J, Dmoszynska A, Wojtaszko M, Zdziarska B, Calbecka M, Kostyra A, Hellmann A, Lewandowski K, Stella-Holowiecka B, Sulek K, Gawronski K, Skotnicki AB, Nowak W, Zawilska K, Molendowicz-Portala L, Kloczko J, Sokolowski J, Warzocha K, Seferynska I, Ceglarek B, Konopka L . Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial . Blood . 109 . 9 . 3672–3675 . May 2007 . 17209059 . 10.1182/blood-2006-08-042929 . free .
  73. Saven A, Burian C, Adusumalli J, Koziol JA . Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia . Blood . 93 . 8 . 2471–2477 . April 1999 . 10194424 . 10.1182/blood.V93.8.2471 .
  74. Dearden CE, Matutes E, Cazin B, Tjønnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SM, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJ, Catovsky D . High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H . Blood . 98 . 6 . 1721–1726 . September 2001 . 11535503 . 10.1182/blood.V98.6.1721 . 26664911 . free .
  75. Web site: JMMLfoundation.org . JMMLfoundation.org . 29 August 2010 . dead . https://web.archive.org/web/20090125041058/http://www.jmmlfoundation.org/modules.php?name=Content&pa=showpage&pid=8%2F . 25 January 2009 .
  76. Stock W . Adolescents and young adults with acute lymphoblastic leukemia . Hematology. American Society of Hematology. Education Program . 2010 . 21–29 . 2010 . 21239766 . 10.1182/asheducation-2010.1.21 . 9796380 . free .
  77. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 . Lancet . 380 . 9859 . 2095–2128 . December 2012 . 23245604 . 10.1016/S0140-6736(12)61728-0 . 10790329 . free . 1541253 . 10536/DRO/DU:30050819 .
  78. Cancer incidence, mortality and survival by site for 14 regions of the world. Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ . Global Programme on Evidence for Health Policy Discussion Paper No. 13. World Health Organization. 2001.
  79. Book: World Cancer Report 2014.. 2014. World Health Organization. 978-92-832-0429-9. Chapter 5.13.
  80. Amitay EL, Keinan-Boker L . Breastfeeding and Childhood Leukemia Incidence: A Meta-analysis and Systematic Review . JAMA Pediatrics . 169 . 6 . e151025 . June 2015 . 26030516 . 10.1001/jamapediatrics.2015.1025 . free .
  81. Web site: Leukemia Facts & Statistics. . https://web.archive.org/web/20090416060712/http://www.leukemia-lymphoma.org/all_page?item_id=9346 . 16 April 2009 . The Leukemia & Lymphoma Society. . 2 July 2009 .
  82. Web site: SEER Cancer Statistics Review, 1975–2006. Surveillance Epidemiology and End Results (SEER). National Cancer Institute. Horner MJ, Ries LA, Krapcho M, Neyman N, etal . Bethesda, MD. 3 November 2009. Table 1.4: Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival Rates By Primary Cancer Site, Sex and Time Period. live. https://web.archive.org/web/20090926004001/http://seer.cancer.gov/csr/1975_2006/. 26 September 2009.
  83. Book: Gurney JG, Smith MA, Ross JA . 1999 . Cancer Incidence and Survival among Children and Adolescents, United States SEER program 1975–1995 . http://www.seer.cancer.gov/publications/childhood/leukemia.pdf . Leukemia . https://web.archive.org/web/20101224153901/http://seer.cancer.gov/publications/childhood/leukemia.pdf . 24 December 2010 . Cancer Statistics Branch, National Cancer Institute .
  84. Web site: Childhood Blood Cancers . The Leukemia & Lymphoma Society . https://web.archive.org/web/20120905211115/http://www.lls.org/diseaseinformation/getinformationsupport/factsstatistics/childhoodbloodcancers/ . 5 September 2012 .
  85. Web site: Facts 2012 . The Leukemia & Lymphoma Society . https://web.archive.org/web/20121014092708/http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/generalcancer/pdf/facts.pdf . 14 October 2012 .
  86. Web site: Leukaemia in Australia statistics. canceraustralia.gov.au. 2023. 3 April 2023.
  87. Web site: Leukaemia (all subtypes combined) statistics. Cancer Research UK. 27 October 2014. live. https://web.archive.org/web/20141007152651/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/leukaemia/. 7 October 2014.
  88. Thomas . Xavier . 2013-08-06 . First contributors in the history of leukemia . World Journal of Hematology . en . 2 . 3 . 62–70 . 10.5315/wjh.v2.i3.62. free .
  89. Ribatti D . Sidney Farber and the treatment of childhood acute lymphoblastic leukemia with a chemotherapeutic agent . Pediatric Hematology and Oncology . 29 . 4 . 299–302 . May 2012 . 22568792 . 10.3109/08880018.2012.678969 . 31176962 .
  90. Patlak M . Targeting leukemia: from bench to bedside . FASEB Journal . 16 . 3 . 273 . March 2002 . 11874976 . 10.1096/fj.02-0029bkt . free . 221751708 .
  91. Web site: Leukemia: MedlinePlus Medical Encyclopedia . MedlinePlus . 8 May 2019 . 16 May 2019.
  92. Web site: leukemia . Online Etymology Dictionary . 14 February 2023.
  93. Book: Sontag S . Illness as Metaphor. Farrar, Straus and Giroux. New York. 1978. 18. 978-0-374-17443-9. Illness as Metaphor.
  94. Bey B . Cancer as Metaphor: The Metaphorical Implications of Romanticized Illness in Young Adult Fiction. 2017. English Honors. Trinity University. 5-6.
  95. Web site: A Snapshot of Leukemia. NCI. 18 June 2014. live. https://web.archive.org/web/20140704183430/http://www.cancer.gov/researchandfunding/snapshots/leukemia. 4 July 2014. dmy-all.
  96. Web site: Search of: leukemia — List Results — ClinicalTrials.gov. live. https://web.archive.org/web/20100915043150/http://clinicaltrials.gov/ct2/results?term=Leukemia. 15 September 2010.
  97. Web site: Learn About Clinical Studies – Reasons for Conducting Clinical Studies . 2023-03-03 . Clinicaltrials.gov . en.
  98. Web site: Understanding Clinical Trials for Blood Cancers. Leukemia and Lymphoma Society. 19 May 2010. dead. https://web.archive.org/web/20110105213515/http://www.leukemia-lymphoma.org/attachments/National/br_1162487596.pdf. 5 January 2011.
  99. Web site: Jaslow R . New Leukemia Therapy Destroys Cancer by Turning Blood Cells into "Assassins". 11 August 2011 . CBSnews.com HealthPop section. 11 August 2011. live. https://web.archive.org/web/20140331173850/http://www.cbsnews.com/news/new-leukemia-therapy-destroys-cancer-by-turning-blood-cells-into-assassins/. 31 March 2014.
  100. Web site: Coghlan A . 26 March 2013 . Gene therapy cures leukaemia in eight days . https://web.archive.org/web/20150515211530/http://www.newscientist.com/article/mg21729104.100-gene-therapy-cures-leukaemia-in-eight-days.html . 15 May 2015 . The New Scientist . 15 April 2013 .
  101. Zhao J, Song Y, Liu D . Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia . Journal of Hematology & Oncology . 12 . 1 . 17 . February 2019 . 30764841 . 6376657 . 10.1186/s13045-019-0705-x . free .
  102. Zheng PP, Kros JM, Li J . Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts . Drug Discovery Today . 23 . 6 . 1175–1182 . June 2018 . 29501911 . 10.1016/j.drudis.2018.02.012 . free . 1765/105338 . free .
  103. Web site: Leukaemia & Lymphoma Research. How we're beating leukaemia. 24 September 2013. live. https://web.archive.org/web/20130927031151/http://leukaemialymphomaresearch.org.uk/research/how-were-beating-blood-cancers/how-were-beating-leukaemia. 27 September 2013.
  104. Koren G, Lishner M . Pregnancy and commonly used drugs in hematology practice . Hematology. American Society of Hematology. Education Program . 2010 . 160–165 . 2010 . 21239787 . 10.1182/asheducation-2010.1.160 . 21832575 . free .
  105. Shapira T, Pereg D, Lishner M . How I treat acute and chronic leukemia in pregnancy . Blood Reviews . 22 . 5 . 247–259 . September 2008 . 18472198 . 10.1016/j.blre.2008.03.006 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Leukemia".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.